Kezar Life Sciences, Inc. (KZR) Change in Accured Expenses (2017 - 2026)

Kezar Life Sciences has reported Change in Accured Expenses for 10 years, with the latest figure at -$2.8 million in Q1 2026.

• Quarterly Change in Accured Expenses rose 21.05% year-over-year to -$2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.6 million (down 76.25% YoY) and the FY2025 annual result came in at -$7.3 million, down 133.25% from the prior year.
• Change in Accured Expenses fell to -$2.8 million in Q1 2026 per KZR's latest filing, from -$590000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $2.9 million in Q3 2023 and troughed at -$3.6 million in Q1 2025.
• A 5-year average of -$303705.9 and a median of -$97000.0 in 2024 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2025: Change in Accured Expenses jumped 379.5% in 2023, then slumped 2709.28% in 2025.
• Over 5 years, Change in Accured Expenses stood at $200000.0 in 2022, then surged by 379.5% to $959000.0 in 2023, then sank by 260.48% to -$1.5 million in 2024, then surged by 61.66% to -$590000.0 in 2025, then sank by 381.36% to -$2.8 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$2.8 million, -$590000.0, and -$426000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.